{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:51:17Z","timestamp":1792785077013,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":108,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Program for Clinical Treatment Research in the Specialist Health Services"},{"name":"The Norwegian Cancer Society","award":["(grant # 190170)"],"award-info":[{"award-number":["(grant # 190170)"]}],"id":[{"id":"https:\/\/ror.org\/01925vb10","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Program for Clinical Treatment Research in the Specialist Health Services (KLINBEFORSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Grade 4 glioma is inherently lethal due to inevitable recurrence. Current radiotherapy guidelines recommend uniform target volume margins, disregarding molecular and clinical variables. We hypothesized that spatiotemporal recurrence may be predicted by molecular and phenotypic features present already at diagnosis. We analyzed 390 paired MRIs of grade 4 gliomas from Norwegian multi-centers and TCIA (2015\u20132025). Deep learning segmentation identified contrast-enhancing (CEcore) and non-enhancing (NE) tumor compartments and afflicted anatomical regions. We quantified primary CEcore\/NE volume ratio, anatomical tumor trajectories, and spatiotemporal progression using Hausdorff-95\u2014analyzed in relation to survival,\n                    <jats:italic>MGMT<\/jats:italic>\n                    ,\n                    <jats:italic>IDH<\/jats:italic>\n                    , age, extent of resection, sex, and anatomical location, using machine learning and Cox regression. Primary tumor composition was independently prognostic: CEcore\/NE volume ratio \u22640.324 predicted improved overall survival (adjusted HR\u2009=\u20090.56, 95% CI 0.37\u20130.84,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006), independent of age,\n                    <jats:italic>MGMT<\/jats:italic>\n                    -status, and individual compartments. Within\n                    <jats:italic>IDH<\/jats:italic>\n                    -wildtype,\n                    <jats:italic>MGMT<\/jats:italic>\n                    -unmethylated patients, low volume ratio \u22640.324 demonstrated a 4.3 months survival benefit (median 17.6 vs 13.3 months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0209). Longer time to progression correlated with increased HD95 distances (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.03). Tumors originating in occipital lobe had highest propensity to migrate to new sites (57.1%) and the shortest time to progression (adjusted HR\u2009=\u20091.90,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.026). These findings support molecular-demographic-anatomical risk stratification that may inform personalized margin-determination in radiotherapy planning.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01557-0","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:23:06Z","timestamp":1781310186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spatial-temporal recurrence patterns of grade 4 glioma using deep learning integrated multiparametric MRI and molecular pathology"],"prefix":"10.1038","volume":"10","author":[{"given":"Marianne H.","family":"Hannisdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvid","family":"Lundervold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Goplen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorunn","family":"Brekke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohummad A.","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Brandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tora S.","family":"Solheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein Atle","family":"Lie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nello","family":"Blaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Chekenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"1557_CR1","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price, M. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021. Neuro Oncol. 26, vi1\u2013vi85 (2024).","journal-title":"Neuro Oncol."},{"key":"1557_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3171\/2011.2.JNS10998","volume":"115","author":"N Sanai","year":"2011","unstructured":"Sanai, N., Polley, M. Y., McDermott, M. W., Parsa, A. T. & Berger, M. S. An extent of resection threshold for newly diagnosed glioblastomas. J. Neurosurg. 115, 3\u20138 (2011). 2011\/03\/23.","journal-title":"J. Neurosurg."},{"key":"1557_CR3","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/0360-3016(89)90941-3","volume":"16","author":"KE Wallner","year":"1989","unstructured":"Wallner, K. E., Galicich, J. H., Krol, G., Arbit, E. & Malkin, M. G. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J. Radiat. Oncol. Biol. Phys. 16, 1405\u20131409 (1989).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"1557_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/neuonc\/noac198","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom, Q. T. et al. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro Oncol. 25, 799\u2013807 (2023).","journal-title":"Neuro Oncol."},{"key":"1557_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997\u20131003 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1557_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459\u2013466 (2009).","journal-title":"Lancet Oncol."},{"key":"1557_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3171\/jns.1978.49.3.0333","volume":"49","author":"MD Walker","year":"1978","unstructured":"Walker, M. D. et al. Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 49, 333\u2013343 (1978).","journal-title":"J. Neurosurg."},{"key":"1557_CR8","doi-asserted-by":"publisher","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","volume":"184","author":"M Niyazi","year":"2023","unstructured":"Niyazi, M. et al. ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma. Radiother. Oncol. 184, 109663 (2023).","journal-title":"Radiother. Oncol."},{"key":"1557_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.11.024","volume":"181","author":"G Minniti","year":"2023","unstructured":"Minniti, G. et al. Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis. Radiother. Oncol. 181, 109435 (2023).","journal-title":"Radiother. Oncol."},{"key":"1557_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11060-022-04123-3","volume":"160","author":"S Shidoh","year":"2022","unstructured":"Shidoh, S. et al. Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation. J. Neurooncol 160, 115\u2013125 (2022).","journal-title":"J. Neurooncol"},{"key":"1557_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2008.19.4969","volume":"27","author":"AA Brandes","year":"2009","unstructured":"Brandes, A. A. et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J. Clin. Oncol. 27, 1275\u20131279 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1557_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9","volume":"67","author":"A Giese","year":"1996","unstructured":"Giese, A. et al. Dichotomy of astrocytoma migration and proliferation. Int. J. Cancer 67, 275\u2013282 (1996).","journal-title":"Int. J. Cancer"},{"key":"1557_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.wneu.2017.04.053","volume":"103","author":"M Rapp","year":"2017","unstructured":"Rapp, M. et al. Recurrence pattern analysis of primary glioblastoma. World Neurosurg. 103, 733\u2013740 (2017).","journal-title":"World Neurosurg."},{"key":"1557_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26\u201341 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"1557_CR15","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1073\/pnas.0808698106","volume":"106","author":"AT Argaw","year":"2009","unstructured":"Argaw, A. T., Gurfein, B. T., Zhang, Y., Zameer, A. & John, G. R. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc. Natl. Acad. Sci. USA 106, 1977\u20131982 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1557_CR16","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1093\/brain\/awz331","volume":"142","author":"CJ Herting","year":"2019","unstructured":"Herting, C. J. et al. Tumour-associated macrophage-derived interleukin-1 mediates glioblastoma-associated cerebral oedema. Brain 142, 3834\u20133851 (2019).","journal-title":"Brain"},{"key":"1557_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","volume":"17","author":"H Lin","year":"2024","unstructured":"Lin, H. et al. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J. Hematol. Oncol. 17, 31 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"1557_CR18","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1158\/0008-5472.CAN-16-2310","volume":"77","author":"Z Chen","year":"2017","unstructured":"Chen, Z. et al. Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Res 77, 2266\u20132278 (2017).","journal-title":"Cancer Res"},{"key":"1557_CR19","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/neuonc\/now258","volume":"19","author":"N Colwell","year":"2017","unstructured":"Colwell, N. et al. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro Oncol. 19, 887\u2013896 (2017).","journal-title":"Neuro Oncol."},{"key":"1557_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature16071","volume":"528","author":"M Osswald","year":"2015","unstructured":"Osswald, M. et al. Brain tumour cells interconnect to a functional and resistant network. Nature 528, 93\u201398 (2015).","journal-title":"Nature"},{"key":"1557_CR21","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/neuonc\/noaa275","volume":"23","author":"R Xie","year":"2021","unstructured":"Xie, R. et al. Tumor cell network integration in glioma represents a stemness feature. Neuro Oncol. 23, 757\u2013769 (2021).","journal-title":"Neuro Oncol."},{"key":"1557_CR22","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1148\/92.3.626","volume":"92","author":"LA Du Sault","year":"1969","unstructured":"Du Sault, L. A. Reoxygenation of tumors during fractionated radiotherapy. Radiology 92, 626\u2013628 (1969).","journal-title":"Radiology"},{"key":"1557_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45067-8","volume":"15","author":"L Hai","year":"2024","unstructured":"Hai, L. et al. A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1. Nat. Commun. 15, 968 (2024).","journal-title":"Nat. Commun."},{"key":"1557_CR24","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3171\/2024.4.JNS232658","volume":"141","author":"X Zhao","year":"2024","unstructured":"Zhao, X. et al. Subventricular zone-associated classification in isocitrate dehydrogenase-wildtype glioblastomas: improved prognostic value through integration of FLAIR with contrast-enhanced imaging. J. Neurosurg. 141, 1304\u20131313 (2024).","journal-title":"J. Neurosurg."},{"key":"1557_CR25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3174\/ajnr.A6025","volume":"40","author":"A Lasocki","year":"2019","unstructured":"Lasocki, A. & Gaillard, F. Non-contrast-enhancing tumor: a new frontier in glioblastoma research. AJNR Am. J. Neuroradiol. 40, 758\u2013765 (2019).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"1557_CR26","unstructured":"Network, N. C. C. Nervous System. Cancers. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Central, 2025). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf."},{"key":"1557_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.prro.2016.03.007","volume":"6","author":"AR Cabrera","year":"2016","unstructured":"Cabrera, A. R. et al. Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pr. Radiat. Oncol. 6, 217\u2013225 (2016).","journal-title":"Pr. Radiat. Oncol."},{"key":"1557_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-03047-9","volume":"23","author":"D Kawauchi","year":"2023","unstructured":"Kawauchi, D. et al. Clinical characteristics and prognosis of glioblastoma patients with infratentorial recurrence. BMC Neurol. 23, 9 (2023).","journal-title":"BMC Neurol."},{"key":"1557_CR29","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1093\/neuonc\/noad109","volume":"25","author":"M Ratliff","year":"2023","unstructured":"Ratliff, M. et al. Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression. Neuro Oncol. 25, 2150\u20132162 (2023).","journal-title":"Neuro Oncol."},{"key":"1557_CR30","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00401-013-1173-y","volume":"126","author":"A Kathagen","year":"2013","unstructured":"Kathagen, A. et al. Hypoxia and oxygenation induce a metabolic switch between pentose phosphate pathway and glycolysis in glioma stem-like cells. Acta Neuropathol. 126, 763\u2013780 (2013).","journal-title":"Acta Neuropathol."},{"key":"1557_CR31","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1541-7786.MCR-17-0680","volume":"16","author":"DH Heiland","year":"2018","unstructured":"Heiland, D. H. et al. Microenvironment-derived regulation of HIF signaling drives transcriptional heterogeneity in glioblastoma multiforme. Mol. Cancer Res. 16, 655\u2013668 (2018).","journal-title":"Mol. Cancer Res."},{"key":"1557_CR32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccell.2015.07.013","volume":"28","author":"J Kim","year":"2015","unstructured":"Kim, J. et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell 28, 318\u2013328 (2015).","journal-title":"Cancer Cell"},{"key":"1557_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98\u2013110 (2010).","journal-title":"Cancer Cell"},{"key":"1557_CR34","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/neuonc\/noae108","volume":"26","author":"ME Hegi","year":"2024","unstructured":"Hegi, M. E. et al. No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic\/NOA-08 trials in elderly glioblastoma patients. Neuro Oncol. 26, 1867\u20131875 (2024).","journal-title":"Neuro Oncol."},{"key":"1557_CR35","first-page":"86","volume":"7","author":"N Kumar","year":"2020","unstructured":"Kumar, N. et al. Impact of volume of irradiation on survival and quality of life in glioblastoma: a prospective, phase 2, randomized comparison of RTOG and MDACC protocols. Neurooncol Pr. 7, 86\u201393 (2020).","journal-title":"Neurooncol Pr."},{"key":"1557_CR36","first-page":"249","volume":"11","author":"D Di Perri","year":"2024","unstructured":"Di Perri, D. et al. Impact of clinical target volume margin reduction in glioblastoma patients treated with concurrent chemoradiation. Neurooncol Pr. 11, 249\u2013254 (2024).","journal-title":"Neurooncol Pr."},{"key":"1557_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2025.101717","volume":"10","author":"JK Matsui","year":"2025","unstructured":"Matsui, J. K. et al. Reduced treatment volumes for glioblastoma associated with lower rates of radionecrosis and lymphopenia: a pooled analysis. Adv. Radiat. Oncol. 10, 101717 (2025).","journal-title":"Adv. Radiat. Oncol."},{"key":"1557_CR38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/iid3.315","volume":"8","author":"MA Rahman","year":"2020","unstructured":"Rahman, M. A. et al. Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: a phase 1B study. Immun. Inflamm. Dis. 8, 342\u2013359 (2020).","journal-title":"Immun. Inflamm. Dis."},{"key":"1557_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11060-020-03574-w","volume":"149","author":"K Akeret","year":"2020","unstructured":"Akeret, K. et al. Distinct topographic-anatomical patterns in primary and secondary brain tumors and their therapeutic potential. J. Neurooncol. 149, 73\u201385 (2020).","journal-title":"J. Neurooncol."},{"key":"1557_CR40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00701-024-05981-8","volume":"166","author":"M Kanamori","year":"2024","unstructured":"Kanamori, M. et al. Distant recurrence in the cerebellar dentate nucleus through the dentato-rubro-thalamo-cortical pathway in supratentorial glioma cases. Acta Neurochir. 166, 83 (2024).","journal-title":"Acta Neurochir."},{"key":"1557_CR41","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.celrep.2016.05.042","volume":"15","author":"CL Smith","year":"2016","unstructured":"Smith, C. L. et al. Migration phenotype of brain-cancer cells predicts patient outcomes. Cell Rep. 15, 2616\u20132624 (2016).","journal-title":"Cell Rep."},{"key":"1557_CR42","doi-asserted-by":"publisher","first-page":"e0281166","DOI":"10.1371\/journal.pone.0281166","volume":"18","author":"H Blakstad","year":"2023","unstructured":"Blakstad, H. et al. Survival in a consecutive series of 467 glioblastoma patients: association with prognostic factors and treatment at recurrence at two independent institutions. PLoS ONE 18, e0281166 (2023).","journal-title":"PLoS ONE"},{"key":"1557_CR43","doi-asserted-by":"publisher","first-page":"20260224","DOI":"10.1007\/s11060-026-05481-y","volume":"177","author":"EE Mendoza Mireles","year":"2026","unstructured":"Mendoza Mireles, E. E. et al. Extent of resection and perioperative neurological status as prognostic markers in glioblastoma: a population-based study. J. Neurooncol. 177, 20260224 (2026).","journal-title":"J. Neurooncol."},{"key":"1557_CR44","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"1557_CR45","doi-asserted-by":"publisher","unstructured":"Bakas, S. et al. Multi-parametric magnetic resonance imaging (mpMRI) scans for de novo Glioblastoma (GBM) patients from the University of Pennsylvania Health System (UPENN-GBM), The Cancer Imaging Archive (2021). https:\/\/doi.org\/10.7937\/TCIA.709X-DN49.","DOI":"10.7937\/TCIA.709X-DN49"},{"key":"1557_CR46","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1557_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jneumeth.2016.03.001","volume":"264","author":"X Li","year":"2016","unstructured":"Li, X., Morgan, P. S., Ashburner, J., Smith, J. & Rorden, C. The first step for neuroimaging data analysis: DICOM to NIfTI conversion. J. Neurosci. Methods 264, 47\u201356 (2016).","journal-title":"J. Neurosci. Methods"},{"key":"1557_CR48","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/neuonc\/noac193","volume":"25","author":"P Karschnia","year":"2023","unstructured":"Karschnia, P. et al. Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. Neuro Oncol. 25, 940\u2013954 (2023).","journal-title":"Neuro Oncol."},{"key":"1557_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33781-0","volume":"13","author":"JE Iglesias","year":"2023","unstructured":"Iglesias, J. E. A ready-to-use machine learning tool for symmetric multi-modality registration of brain MRI. Sci. Rep. 13, 6657 (2023).","journal-title":"Sci. Rep."},{"key":"1557_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44794-0","volume":"13","author":"HG Pemberton","year":"2023","unstructured":"Pemberton, H. G. et al. Multi-class glioma segmentation on real-world data with missing MRI sequences: comparison of three deep learning algorithms. Sci. Rep. 13, 18911 (2023).","journal-title":"Sci. Rep."},{"key":"1557_CR51","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41592-020-01008-z","volume":"18","author":"F Isensee","year":"2021","unstructured":"Isensee, F., Jaeger, P. F., Kohl, S. A. A., Petersen, J. & Maier-Hein, K. H. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat. Methods 18, 203\u2013211 (2021).","journal-title":"Nat. Methods"},{"key":"1557_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-45456-x","volume":"13","author":"RH Helland","year":"2023","unstructured":"Helland, R. H. et al. Segmentation of glioblastomas in early post-operative multi-modal MRI with deep neural networks. Sci. Rep. 13, 18897 (2023).","journal-title":"Sci. Rep."},{"key":"1557_CR53","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/S1470-2045(19)30098-1","volume":"20","author":"P Kickingereder","year":"2019","unstructured":"Kickingereder, P. et al. Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. Lancet Oncol. 20, 728\u2013740 (2019).","journal-title":"Lancet Oncol."},{"key":"1557_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad037","volume":"5","author":"MH Hannisdal","year":"2023","unstructured":"Hannisdal, M. H. et al. Feasibility of deep learning-based tumor segmentation for target delineation and response assessment in grade 4 glioma using multi-parametric MRI. Neuro Oncol. Adv. 5, vdad037 (2023).","journal-title":"Neuro Oncol. Adv."},{"key":"1557_CR55","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.neuroimage.2010.09.025","volume":"54","author":"BB Avants","year":"2011","unstructured":"Avants, B. B. et al. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 54, 2033\u20132044 (2011).","journal-title":"Neuroimage"},{"key":"1557_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add3607","volume":"9","author":"JE Iglesias","year":"2023","unstructured":"Iglesias, J. E. et al. SynthSR: a public AI tool to turn heterogeneous clinical brain scans into high-resolution T1-weighted images for 3D morphometry. Sci. Adv. 9, eadd3607 (2023).","journal-title":"Sci. Adv."},{"key":"1557_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.media.2023.102789","volume":"86","author":"B Billot","year":"2023","unstructured":"Billot, B. et al. SynthSeg: segmentation of brain MRI scans of any contrast and resolution without retraining. Med. Image Anal. 86, 102789 (2023).","journal-title":"Med. Image Anal."},{"key":"1557_CR58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2216399120","volume":"120","author":"B Billot","year":"2023","unstructured":"Billot, B. et al. Robust machine learning segmentation for large-scale analysis of heterogeneous clinical brain MRI datasets. Proc. Natl. Acad. Sci. USA 120, e2216399120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1557_CR59","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan, E. L. & Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457\u2013481 (1958).","journal-title":"J. Am. Stat. Assoc."},{"key":"1557_CR60","first-page":"487","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. Ser. B (Methodol. 34, 487\u2013202 (1972).","journal-title":"J. R. Stat. Soc. Ser. B (Methodol."},{"key":"1557_CR61","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","volume":"95","author":"M Lacroix","year":"2001","unstructured":"Lacroix, M. et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 95, 190\u2013198 (2001).","journal-title":"J. Neurosurg."},{"key":"1557_CR62","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01557-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01557-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01557-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:02:57Z","timestamp":1790640177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01557-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1557"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01557-0","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"364"}}